Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation.
Hyperparathyroidism occurs in most patients during the progression of chronic kidney disease (CKD) and one of its initiating events, reduced serum levels of 1,25-dihydroxyvitamin D, results from a decrease in renal 1alpha hydroxylase activity, which converts 25-hydroxyvitamin D to its activated form. The combination of persistently high parathyroid hormone (PTH) and low 1,25-dihydroxyvitamin D is associated with bone loss, cardiovascular disease, immune suppression and increased mortality in patients with end-stage kidney failure. Recent studies in dialysis patients suggest that paricalcitol, a selective activator of the vitamin D receptor (VDR), is associated with a more favorable efficacy to side effect profile than calcitriol, with less morbidity and better survival. One hypothesis derived from such studies suggests that systemic activation of VDRs may have direct effects on the cardiovascular system to decrease mortality in CKD. Although current guidelines for regulating serum calcium, phosphate and PTH recommend specific interventions at the various stages of CKD to prevent or postpone irreversible parathyroid disease and decrease cardiovascular morbidity and mortality, emerging data suggest that vitamin D therapy may prolong survival in this patient population by mechanisms that are independent of calcium, phosphate and PTH. It is suggested that a re-evaluation of current treatment recommendations is needed and that future research should focus on mechanisms that distinguish potential tissue specific benefits of selective VDR activators in patients with CKD.
Andress
D L
DL
Department of Medicine, VA Puget Sound Health Care System, Division of Nephrology, University of Washington, Seattle, Washington, USA. dandress@u.washington.edu
D000818:Animals; D050197:Atherosclerosis / Q000517:prevention & control; D001862:Bone Resorption / Q000150:complications; D002114:Calcinosis / Q000209:etiology; D002908:Chronic Disease; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000209:etiology; D007674:Kidney Diseases / Q000188:drug therapy* / Q000401:mortality; D018167:Receptors, Calcitriol / Q000502:physiology*; D006435:Renal Dialysis / Q000401:mortality; D014652:Vascular Diseases / Q000209:etiology; D014807:Vitamin D / Q000378:metabolism / Q000627:therapeutic use*
D018167:Receptors, Calcitriol; D014807:Vitamin D